WHAT ARE THE RISKS?

UP TO a third of patients develop inflammation affecting the brain. This can cause tiredness, headaches and seizures, and usually resolves spontaneously.

ABOUT 20 per cent of patients develop a flu-like condition known as cytokine release syndrome caused by the release of immune substances. It indicates the therapy is having an effect.

ROSE GRAY, from Cancer Research UK, says: ‘It’s exciting to see developments in immunotherapy for people with blood cancers. ‘CAR T-cell therapies have shown great promise, but are complicated and highly personalised. Research helps us determine who they may work for, as well as how to minimise side-effects.’